122 related articles for article (PubMed ID: 14730468)
1. Canertinib pfizer.
Galmarini CM
IDrugs; 2004 Jan; 7(1):58-63. PubMed ID: 14730468
[TBL] [Abstract][Full Text] [Related]
2. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri TK
Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
[TBL] [Abstract][Full Text] [Related]
3. PTK/ZK (Novartis).
Drevs J
IDrugs; 2003 Aug; 6(8):787-94. PubMed ID: 12917775
[TBL] [Abstract][Full Text] [Related]
4. Edotecarin.
Denny WA
IDrugs; 2004 Feb; 7(2):173-7. PubMed ID: 15057663
[TBL] [Abstract][Full Text] [Related]
5. OSI-774 OSI Pharmaceuticals.
Norman P
Curr Opin Investig Drugs; 2001 Feb; 2(2):298-304. PubMed ID: 11816847
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: pegaptanib, Eyetech/Pfizer.
Vinores SA
Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
[TBL] [Abstract][Full Text] [Related]
7. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
Hu-Lowe D; Brega N; Patyna S
Mol Cancer Ther; 2011 Nov; 10(11):2015. PubMed ID: 22072801
[No Abstract] [Full Text] [Related]
8. The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo.
Djerf Severinsson EA; Trinks C; Gréen H; Abdiu A; Hallbeck AL; Stål O; Walz TM
Biochem Biophys Res Commun; 2011 Oct; 414(3):563-8. PubMed ID: 21982771
[TBL] [Abstract][Full Text] [Related]
9. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA; Fekrazad HM; Verschraegen CF
Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Kell J
Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller ML
Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
13. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
14. EPO-906 (Novartis).
Galmarini CM; Dumontet C
IDrugs; 2003 Dec; 6(12):1182-7. PubMed ID: 14666430
[TBL] [Abstract][Full Text] [Related]
15. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
16. Technology evaluation: AVI-4126, AVI BioPharma.
Stephens AC
Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
[TBL] [Abstract][Full Text] [Related]
17. Technology evaluation: ABT-510, Abbott.
Westphal JR
Curr Opin Mol Ther; 2004 Aug; 6(4):451-7. PubMed ID: 15468604
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol. National Cancer Institute.
Wang HK
Curr Opin Investig Drugs; 2001 Aug; 2(8):1149-55. PubMed ID: 11892928
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
20. ISIS-3521. Isis Pharmaceuticals.
Li K; Zhang J
Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]